Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su CDPATH™ per aiutare a gestire e curare la malattia di Crohn (COMPASS-CD)

5 ottobre 2026 aggiornato da: Takeda

Uno studio di fase 4 che valuta l'uso nel mondo reale di CDPATH™, uno strumento di previsione del rischio di malattia di Crohn

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

241

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda, California, Stati Uniti, 92357
        • VA Loma Linda Healthcare System
      • Murrieta, California, Stati Uniti, 92563
        • United Medical Doctors
      • Newport Beach, California, Stati Uniti, 92663
        • University of Southern California Medical Center
      • Orange, California, Stati Uniti, 92868
        • University of California at Irvine Medical Center
      • Orange, California, Stati Uniti, 92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden, Connecticut, Stati Uniti, 06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater, Florida, Stati Uniti, 33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola, Florida, Stati Uniti, 32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls, Idaho, Stati Uniti, 83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights, Illinois, Stati Uniti, 60005
        • GI Alliance
      • Gurnee, Illinois, Stati Uniti, 60031
        • GI Alliance
      • Northbrook, Illinois, Stati Uniti, 60062
        • Comprehensive Gastrointestinal Health
      • Rockford, Illinois, Stati Uniti, 61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Indiana University
    • Iowa
      • Clive, Iowa, Stati Uniti, 50325
        • Iowa Digestive Disease Center
      • Iowa City, Iowa, Stati Uniti, 52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge, Louisiana, Stati Uniti, 70809
        • GI Alliance - Baton Rouge
      • Shreveport, Louisiana, Stati Uniti, 71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia, Maryland, Stati Uniti, 21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington, Massachusetts, Stati Uniti, 01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester, Massachusetts, Stati Uniti, 01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87131-0001
        • University of New Mexico
    • New York
      • New York, New York, Stati Uniti, 10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek, Ohio, Stati Uniti, 45431
        • Clinical Inquest Center Ltd
      • Dayton, Ohio, Stati Uniti, 45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland, Oregon, Stati Uniti, 97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill, Pennsylvania, Stati Uniti, 17011
        • Susquehanna Research Group, LLC
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh, Pennsylvania, Stati Uniti, 15212
        • Allegheny Center for Digestive Health
      • Uniontown, Pennsylvania, Stati Uniti, 15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville, South Carolina, Stati Uniti, 29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, Stati Uniti, 57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin, Texas, Stati Uniti, 78712
        • The University of Texas at Austin
      • Houston, Texas, Stati Uniti, 77030
        • Baylor College of Medicine
      • Southlake, Texas, Stati Uniti, 76092
        • GI Alliance - Southlake
    • Utah
      • Ogden, Utah, Stati Uniti, 84403
        • Care Access Research Berkley
      • Salt Lake City, Utah, Stati Uniti, 84132
        • University of Utah
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • GCGA Physicians LLC
      • Lynchburg, Virginia, Stati Uniti, 24502
        • Gastroenterology Associates
    • Washington
      • Bellevue, Washington, Stati Uniti, 98405
        • GI Alliance

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

Altri nomi:
  • PROSPETTIVA

Three blood samples will be drawn.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Lasso di tempo: Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Lasso di tempo: Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
Lasso di tempo: Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Lasso di tempo: Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Lasso di tempo: Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Lasso di tempo: Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
Lasso di tempo: Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
Lasso di tempo: Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Lasso di tempo: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Study Director, Takeda

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 giugno 2021

Completamento primario (Effettivo)

27 agosto 2026

Completamento dello studio (Effettivo)

27 agosto 2026

Date di iscrizione allo studio

Primo inviato

19 marzo 2021

Primo inviato che soddisfa i criteri di controllo qualità

19 marzo 2021

Primo Inserito (Effettivo)

22 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • Vedolizumab-4015

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Criteri di accesso alla condivisione IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .